#include ./header_include.iphtml
<p align="center"><font 
color="#0c2d83"><b><font color="#0c2d83" size="+2">Article Reviews and Commentary</font></b></font> 
<p>&nbsp;
<p><font color="#0c2d83" size="+1">Omalizumab Improves Asthma-related Quality 
  of Life in Children with Allergic Asthma<br>
  </font> 
Lemanske RF, Nayak A, McAlary M et al. Pediatrics 2002;110(5) 
<p><a href="http://www.pediatrics.org/cgi/content/full/110/e55">www.pediatrics.org/cgi/content/full/110/e55</a> 
<p> 
<p>Omalizumab is a recombinant, monoclonal anti-IgE antibody developed as a treatment 
  of IgE-mediated asthma and other IgE-mediated conditions. Other reports have 
  shown that children with allergic asthma have treated with Omalizumab had reduced 
  requirements for inhaled steroids. The authors here report part of the results 
  of a 28 week, randomized, double-blind, placebo-controlled study of omaalizumab. 
  Children who were enrolled were well-controlled with daily inhaled corticosteroids. 
  During the course of the study, the dose of inhaled steroid was reduced and 
  throughout the Pediatric Asthma Quality of Life Questionaire (PAQLQ) was administered 
  to the participating families. Based on the responses to the PAQLQ the children 
  had fewer symptoms and improvement in their participation in activities. 
<p> 
<blockquote>
  <p><b><i>Commentary Thomas J. Mancuso, MD, FAAP</i></b> </p>
  <p>Please don't ask me to pronounce this medication! This paper is included 
    to illustrate the advances in outpatient management of asthma. </p>
</blockquote>
#include ./footer_include.iphtml